Cargando…
Secukinumab Therapy in Refractory Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA), the most common chronic rheumatologic condition in childhood, remains a cause of significant morbidity, particularly in those with spondyloarthropathy, including psoriatic arthritis (PsA) and enthesitis-related arthritis (ERA). While secukinumab was recently appr...
Autores principales: | Nelson, Meghan Corrigan, Manos, Cynthia K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515513/ https://www.ncbi.nlm.nih.gov/pubmed/37731263 http://dx.doi.org/10.1177/23247096231200403 |
Ejemplares similares
-
Secukinumab-Induced Crohn's Disease in a Patient Treated for Juvenile Idiopathic Arthritis
por: Edupuganti, Srujan, et al.
Publicado: (2023) -
Juvenile idiopathic arthritis
por: Bhatt, Krupa H, et al.
Publicado: (2014) -
Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis
por: William, Mridula, et al.
Publicado: (2012) -
COVID-19 after rituximab therapy in cSLE patients
por: Nelson, Meghan Corrigan, et al.
Publicado: (2023) -
Mineral Oil Aspiration Related Juvenile Idiopathic Arthritis
por: Nelson, Andrew D., et al.
Publicado: (2015)